Winter 2017/18 Teasers
Drug Discovery World
Use of Next-Generation Sequencing in the regulated domain of drug development
By Keith Nangle & Mike Furness

Next-Generation Sequencing is moving quickly from early research into the regulated domains of drug development, diagnostic development, and clinical decision-making.

Next-generation sequencing (NGS) has moved from the realm of research into those of clinical development, drug approval and clinical diagnostics, as the cost has decreased and the reliability of the underlying technologies has increased. However, the process of translating raw reads into reliable genotypes is still subject to much variability. This variability presents a challenge when using NGS in the regulated domain of the drug development process.

You just need to REGISTER - its FREE - to read the rest of this article straight away.